Trial Profile
Phase II trial of an endometrial regenerative stem cell product for congestive heart failure: the RECOVER-ERC trial.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2020
Price :
$35
*
At a glance
- Drugs ERC 124 (Primary)
- Indications Heart failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms RECOVER-ERC
- 22 Mar 2013 Interim safety results published in a Medistem media release.
- 22 Mar 2013 Medistem published an update on RECOVER-ERC in Translational Medicine, according to a company media release.
- 11 Jan 2013 New trial record